Thomas Pabst

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Heterozygous PU.1 mutations are associated with acute myeloid leukemia
    Beatrice U Mueller
    Harvard Institutes of Medicine, Harvard Medical School, Boston, MA, USA
    Blood 100:998-1007. 2002
  2. pmc The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML
    M Eyholzer
    Department of Clinical Research, University of Bern, Bern, Switzerland
    Br J Cancer 103:275-84. 2010
  3. pmc High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma
    J Raschle
    Department of Medical Oncology, University Hospital and University of Berne, Berne, Switzerland
    Br J Cancer 105:970-4. 2011
  4. doi request reprint Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
    Thomas Pabst
    Department of Medical Oncology, University Hospital, Bern, Switzerland
    Blood 119:5367-73. 2012
  5. doi request reprint Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia
    Thomas Pabst
    Department of Medical Oncology, University Hospital, Bern, Switzerland
    J Clin Oncol 26:5088-93. 2008
  6. pmc Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
    T Pabst
    Department of Medical Oncology and Clinical Research, University Hospital Bern and University Bern, Bern, Switzerland
    Br J Cancer 100:1343-6. 2009
  7. doi request reprint Complexity of CEBPA dysregulation in human acute myeloid leukemia
    Thomas Pabst
    Department of Oncology, University Hospital, Bern, Switzerland
    Clin Cancer Res 15:5303-7. 2009
  8. ncbi request reprint Transcriptional dysregulation during myeloid transformation in AML
    T Pabst
    Institute of Medical Oncology, University Hospital, Bern, Switzerland
    Oncogene 26:6829-37. 2007
  9. ncbi request reprint Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia
    Julian A Schardt
    Department of Medical Oncology, University Hospital Bern and University of Bern, Switzerland
    J Cell Mol Med 14:1509-19. 2010
  10. ncbi request reprint CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16)
    Daniel Helbling
    Department of Clinical Research, University Hospital, Berne, Switzerland
    Blood 106:1369-75. 2005

Collaborators

Detail Information

Publications31

  1. ncbi request reprint Heterozygous PU.1 mutations are associated with acute myeloid leukemia
    Beatrice U Mueller
    Harvard Institutes of Medicine, Harvard Medical School, Boston, MA, USA
    Blood 100:998-1007. 2002
    ..1 target genes. This is the first report of mutations in the PU.1 gene in human neoplasia and suggests that disruption of PU.1 function contributes to the block in differentiation found in AML patients...
  2. pmc The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML
    M Eyholzer
    Department of Clinical Research, University of Bern, Bern, Switzerland
    Br J Cancer 103:275-84. 2010
    ..The aim of this study was to investigate the genome-wide pattern of miRNAs regulated by CEBPA in myeloid cells...
  3. pmc High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma
    J Raschle
    Department of Medical Oncology, University Hospital and University of Berne, Berne, Switzerland
    Br J Cancer 105:970-4. 2011
    ..However, only few factors have been identified affecting the outcome in such patients. We hypothesised that varying levels of mobilised CD34+ cells confer prognostic information in myeloma patients undergoing high-dose chemotherapy...
  4. doi request reprint Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
    Thomas Pabst
    Department of Medical Oncology, University Hospital, Bern, Switzerland
    Blood 119:5367-73. 2012
    ..The HOVON-42 study is registered under The Netherlands Trial Registry (www.trialregister.nl) as #NTR230...
  5. doi request reprint Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia
    Thomas Pabst
    Department of Medical Oncology, University Hospital, Bern, Switzerland
    J Clin Oncol 26:5088-93. 2008
    ..Whereas familial AML is considered a rare event, the frequency of CEBPA germline mutations in AML is not known...
  6. pmc Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
    T Pabst
    Department of Medical Oncology and Clinical Research, University Hospital Bern and University Bern, Bern, Switzerland
    Br J Cancer 100:1343-6. 2009
    ..In a multivariable analysis, only double -- but not single -- CEBPA mutations were identified as independent prognostic factors. These findings indicate heterogeneity within AML patients with CEBPA mutations...
  7. doi request reprint Complexity of CEBPA dysregulation in human acute myeloid leukemia
    Thomas Pabst
    Department of Oncology, University Hospital, Bern, Switzerland
    Clin Cancer Res 15:5303-7. 2009
    ..The currently available data are persuasive evidence that impaired CEBPA function contributes directly to the development of AML, whereas restoring CEBPA function represents a promising target for novel therapeutic strategies in AML...
  8. ncbi request reprint Transcriptional dysregulation during myeloid transformation in AML
    T Pabst
    Institute of Medical Oncology, University Hospital, Bern, Switzerland
    Oncogene 26:6829-37. 2007
    ....
  9. ncbi request reprint Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia
    Julian A Schardt
    Department of Medical Oncology, University Hospital Bern and University of Bern, Switzerland
    J Cell Mol Med 14:1509-19. 2010
    ....
  10. ncbi request reprint CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16)
    Daniel Helbling
    Department of Clinical Research, University Hospital, Berne, Switzerland
    Blood 106:1369-75. 2005
    ..Inhibition of calreticulin by siRNA restored CEBPA levels. Our results suggest that modulation of CEBPA by calreticulin represents a novel mechanism involved in the differentiation block in CBFB-SMMHC AML...
  11. doi request reprint Complexity of miR-223 regulation by CEBPA in human AML
    Marianne Eyholzer
    Institute of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010 Bern, Switzerland
    Leuk Res 34:672-6. 2010
    ..Our results suggest that miR-223 suppression in AML is caused by impaired miR-223 upstream factors...
  12. doi request reprint Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia
    Julian A Schardt
    Departments of Medical Oncology and Clinical Research, University Hospital Bern, Bern, Switzerland
    Clin Cancer Res 15:3834-41. 2009
    ..Previous studies suggest that the unfolded protein response is activated in some cancer cell lines and involved in tumor development. The role of the unfolded protein response during leukemogenesis is unknown thus far...
  13. doi request reprint Lineage-specific transcription factor aberrations in AML
    Beatrice U Mueller
    Department of Internal Medicine, University Hospital, 3010, Bern, Switzerland
    Cancer Treat Res 145:109-25. 2010
    ..Here, we intend to review recent findings on aberrations in lineage-restricted transcription factors as observed in patients with acute myeloid leukemia (AML)...
  14. ncbi request reprint The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients
    Sarah Mans
    Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland
    Blood 120:2690-9. 2012
    ..006). Our data indicate that vasostatin is released from cell-surface CRT and impairs differentiation of myeloid cells and vascularization of the bone marrow microenvironment...
  15. pmc Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML
    Simon Haefliger
    Department of Medical Oncology, University Hospital and University of Berne, Berne, Switzerland
    Blood 117:5931-40. 2011
    ..Our results indicate a novel role of PDI as a member of the ER stress-associated complex mediating blocked CEBPA translation and thereby suppressing myeloid differentiation in AML patients with activated unfolded protein response (UPR)...
  16. pmc ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression
    Beatrice U Mueller
    Department of Internal Medicine, University Hospital, 3010 Bern, Switzerland
    Blood 107:3330-8. 2006
    ..This is the first report to show that PU.1 is suppressed in acute promyelocytic leukemia, and that ATRA restores PU.1 expression in cells harboring t(15;17)...
  17. doi request reprint Heterozygous deletion of the PU.1 locus in human AML
    Nicola Bonadies
    Department of Internal Medicine and Clinical Research, University Hospital, and University of Bern, Bern, Switzerland
    Blood 115:331-4. 2010
    ..1 locus. Consistently, PU.1 expression in this patient was markedly reduced. Our study suggests that heterozygous deletion of the PU.1 locus can be associated with human AML...
  18. doi request reprint Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis
    José Fos
    Department of Internal Medicine and Clinical Research, University of Bern, Bern, Switzerland
    Blood 117:4881-4. 2011
    ..These data indicate that suppressed CEBPA function is associated with favorable prognosis in NK-AML patients...
  19. doi request reprint Activation of the unfolded protein response in human acute myeloid leukemia
    Julian A Schardt
    Department of Medical Oncology, University Hospital, Bern, Switzerland
    Methods Enzymol 489:227-43. 2011
    ..From a more clinical point of view, the presence of activated UPR in AML patient samples was found to be associated with a favorable disease course...
  20. ncbi request reprint Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia
    Thomas Pabst
    Institute of Medical Oncology, University Hospital, Berne, Switzerland
    Br J Haematol 133:400-2. 2006
    ..Here, no CEBPA mutation in 95 CML-BC patients was found, suggesting a limited role, if any, of CEBPA mutations in this disorder...
  21. ncbi request reprint Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiency
    Stefano Fontana
    Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
    Transfusion 46:1408-16. 2006
    ..Individual adaptation of processed patient's blood volume (PBV) should reduce number and/or duration of autologous peripheral blood progenitor cell (PBPC) collections...
  22. pmc Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemia
    B U Mueller
    Department of Internal Medicine, University Hospital, Bern, Switzerland
    Br J Cancer 94:1918-20. 2006
    ..1 gene. We found no genomic alteration of the PU.1 gene suggesting that PU.1 mutations are not likely to be common in B-ALL...
  23. ncbi request reprint C/EBPalpha and the pathophysiology of acute myeloid leukemia
    Beatrice U Mueller
    Department of Internal Medicine, University Hospital, Switzerland
    Curr Opin Hematol 13:7-14. 2006
    ..The finding of C/EBPalpha alterations in subgroups of acute myeloid leukemia patients suggests a direct link between critically decreased C/EBPalpha function and the development of the disorder...
  24. doi request reprint A single-centre cohort of patients with systemic light chain AL-amyloidosis treated with conventional chemotherapy or with high-dose chemotherapy and autologous stem cell transplantation
    Joëlle Raschle
    Department of Medical Oncology, University Hospital and University of Berne, Switzerland
    Swiss Med Wkly 144:w13922. 2014
    ..However, only limited data are available so far on treatment and outcome of AL-amyloidosis patients in Switzerland...
  25. pmc The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin
    Daniel Helbling
    Institute of Medical Oncology, University Hospital, CH 3010 Bern, Switzerland
    Proc Natl Acad Sci U S A 101:13312-7. 2004
    ..These results identify CEBPA as a key target of the leukemic fusion protein AME and suggest that modulation of CEBPA by CRT may represent a mechanism involved in the differentiation block in AME leukemias...
  26. doi request reprint The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential
    Isabelle von Grünigen
    Department of Medical Oncology, University Hospital and University of Berne, Berne, Switzerland
    Leuk Res 36:1325-9. 2012
    ..These data suggest that ASCT is associated with unfavorable outcome in AML patients with high levels of mobilized peripheral CD34+ cells...
  27. ncbi request reprint Pneumococcal vaccination in splenectomised cancer patients
    Aurelius G Omlin
    Department of Medical Oncology, University Hospital, 3010 Bern, Switzerland
    Eur J Cancer 41:1731-4. 2005
    ..Repeated assessments of the pneumococcal vaccination status increased the rate of vaccination...
  28. doi request reprint PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer element
    N Bonadies
    Department of Internal Medicine and Clinical Research, University Hospital Bern, University of Bern, Bern, Switzerland
    Oncogene 29:1062-72. 2010
    ..1 mRNA expression. This study suggests that changes of a single base pair in a distal element critically affect the regulation of the tumor suppressor gene PU.1 thereby contributing to the development of AML...
  29. doi request reprint Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells
    Peggy Kirstetter
    European Molecular Biology Laboratory, Mouse Biology Unit, Monterotondo 00016, Italy
    Cancer Cell 13:299-310. 2008
    ..Expression profiling of this population against normal Mac1+c-Kit+ progenitors revealed a signature shared with MLL-AF9-transformed AML...
  30. ncbi request reprint Risk assessment in patients with acute myeloid leukemia and a normal karyotype
    Marianne Bienz
    Institute of Medical Oncology and the Laboratory for Molecular Diagnostics, Department of Hematology, University of Berne, CH 3010 Berne, Switzerland
    Clin Cancer Res 11:1416-24. 2005
    ..There has therefore been much interest in identifying molecular markers that could help to improve the prognostic stratification of patients with normal-karyotype AML...
  31. ncbi request reprint Heterozygous PU.1 mutations are associated with acute myeloid leukemia
    Beatrice U Mueller
    Blood 101:2074. 2003